CHO CLD is a time and resource intensive process. While new vectors and robotics have improved timelines and throughput, they are costly and haven’t solved the core productivity limits of traditional CHO hosts. To address this, we have developed CHOZN® Elite cell line, a production-adapted CHO cell line that delivers high-yield clones using standard plasmids and media — no expensive technology required. Clones from minipool and bulk pool workflows reached up to 13 g/L and 5 g/L respectively with the later attainable in only 80 days. Depending on the CLD method used, this new host cell line meets industrial needs by accelerating the CLD or increasing the titer leading to cost-saving process.
In this webinar, you will learn about:
- Traditional CLD is slow, costly, and limited by CHO host performance
- CHOZN® Elite cell line enables high productivity using standard tools — no expensive tech needed.
- How to save cost by achieving 13g/L in a minipool clone, using a standard plasmid.
- Speeding up the CLD process by achieving 5 g/L in a bulk pool clone in only 80 days.
Speaker
David Razafsky
Merck
Cell Lines R&D Manager
David Razafsky has 10 years of experience in the bioprocessing industry. In his current role, David leads a team whose mission is to develop technologies to improve cell line development and make biologics manufacturing more efficient and cost-effective. To accomplish these goals our team utilizes state of art tools including next-generation sequencing, high-throughput screens and genetic engineering. David holds a Ph.D. in molecular biology & biochemistry and a M.S. in cell biology & biophysics from the University of Missouri, Kansas City, as well as a B.S. in chemical sciences and psychology from Kansas State University.
Pharma and biopharma manufacturing
- Pharma and biopharma manufacturing
期间:1h
语言:English
场次 1:往期 October 16, 2025
如要继续阅读，请登录或创建帐户。
暂无帐户？